Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 10/20 | 0.55 |
| ▸ | POLB | P06746 | 2/20 | 0.55 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.55 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.55 |
| ▸ | CNR1 | P21554 | 1/20 | 0.55 |
| ▸ | ACHE | P22303 | 1/20 | 0.55 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.55 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.55 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.55 |
| ▸ | MC3R | P41968 | 1/20 | 0.55 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.55 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.55 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.55 |
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 3/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11227138 | 0.83 | ADORA2B (0.60) | ADORA2BPOLBPIK3CDADORA3CNR1 | |
| SCHEMBL21363487 | 0.80 | ADORA2B (0.64) | ADORA2BPOLBPIK3CDADORA3CNR1 | |
| SCHEMBL22398942 | 0.78 | ADORA2B (0.62) | ADORA2BPOLBPIK3CDADORA3CNR1 | |
| SCHEMBL1065297 | 0.78 | ADORA2B (0.57) | ADORA2BPOLBPIK3CDADORA3CNR1 | |
| SCHEMBL10112858 | 0.77 | ADORA2B (0.52) | ADORA2BPOLBPIK3CDADORA3CNR1 | |
| Caffeine SCHEMBL23420342 | 0.75 | ADORA2B (0.83) | ADORA2BPOLBPIK3CDADORA3CNR1 | |
| SCHEMBL17626243 | 0.74 | SMN1; SMN2 (0.56) | ADORA2BPOLBPIK3CDADORA3CNR1 | |
| SCHEMBL516014 | 0.73 | ADORA2B (0.72) | ADORA2BPOLBPIK3CDADORA3CNR1 | |
| SCHEMBL16120984 | 0.73 | ADORA2B (0.81) | ADORA2BPOLBPIK3CDADORA3CNR1 | |
| SCHEMBL19969106 | 0.72 | ADORA2B (0.50) | ADORA2BPOLBPIK3CDADORA3CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 166 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120064547-A | Method for detecting dihydroxypropehylline injection | 上海信谊金朱药业有限公司 | 2025-05-30 | — | — | CN | claimed |
| CN-120064407-A | PH sensing method for realizing electrochemical calibration-free based on dynamic current technology | 常州江苏大学工程技术研究院 | 2025-05-30 | — | — | CN | claimed |
| CN-119868268-A | Dihydroxypropyl theophylline injection and preparation method thereof | 江西科为制药有限公司 | 2025-04-25 | — | — | CN | claimed |
| CN-119246866-A | Total bilirubin dry detection and analysis assembly and preparation method thereof | 英科新创(厦门)科技股份有限公司 | 2025-01-03 | — | — | CN | claimed |
| CN-115850278-B | Novel crystal form solid substance of dihydroxypropehylline, preparation method thereof, injection and preparation method thereof | 广州合和医药有限公司 | 2024-06-07 | — | — | CN | claimed |
| CN-118087049-A | Texturing additive for preparing low-reflection solar cell and application thereof | 常州时创能源股份有限公司 | 2024-05-28 | — | — | CN | claimed |
| CN-117999073-A | Use of nadolol to treat chronic obstructive pulmonary disease by blocking the inhibitor protein-2 pathway | 慢性呼吸道治疗有限公司 | 2024-05-07 | — | — | CN | claimed |
| CN-117946812-A | Cleaning composition | 安集微电子科技（上海）股份有限公司 | 2024-04-30 | — | — | CN | claimed |
| CN-114019076-B | Method for simultaneously measuring 5 components in compound hyprolfsteaine dechlorinated hydroxyzine capsules | 苏州市药品检验检测研究中心 | 2024-04-09 | — | — | CN | claimed |
| CN-116693735-A | Use of olefin functional polymer as compatibility modifier | 江苏扬农化工集团有限公司 | 2023-09-05 | — | — | CN | claimed |
| WO-2021217574-A1 | TREATMENT OR PREVENTION OF CORONAVIRIDAE INFECTION | WATERSTONE PHARMACEUTICALS (WUHAN) CO., LTD. (CN) | 2021-11-04 | — | — | WO | claimed |
| US-20040110694-A1 | Novel solid pharmaceutical dispersions | GHEBRE-SELLASSIE ISAAC (US) | 2004-06-10 | — | — | US | claimed |
| CN-1120841-C | Medicine composition and use thereof | BOEHRINGER INGELHEIM KG (DE) | 2003-09-10 | — | — | CN | claimed |
| US-20010044409-A1 | Novel solid pharmaceutical dispersions | GHEBRE-SELLASSIE ISAAC (US) | 2001-11-22 | — | — | US | claimed |
| CN-1191535-A | Novel pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM KG (DE) | 1998-08-26 | — | — | CN | claimed |
| EP-0617612-B1 | A PROCESS FOR THE PREPARATION OF A SOLID DISPERSION | WARNER LAMBERT CO (US) | 1997-09-10 | — | — | EP | claimed |
| EP-0617612-A1 | A PROCESS FOR THE PREPARATION OF A SOLID DISPERSION. | WARNER LAMBERT CO (US) | 1994-10-05 | — | — | EP | claimed |
| WO-1993011749-A1 | A PROCESS FOR THE PREPARATION OF A SOLID DISPERSION | WARNER-LAMBERT COMPANY (US) | 1993-06-24 | — | — | WO | claimed |
| EP-0073302-B1 | PROCESS FOR THE PREPARATION OF DIHYDROXYPROPYLTHEOPHYLLINE | Degussa Aktiengesellschaft (DE) | 1985-05-22 | — | — | EP | claimed |
| US-4405783-A | Process for the production of dihydroxypropyltheophylline | DEGUSSA AKTIENGESELLSCHAFT (DE) | 1983-09-20 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010044409-A1 | Novel solid pharmaceutical dispersions | RPS27A, FUS, ABCG2 | ADORA2B 4225/4885POLB 3308/4885PIK3CD 3117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.